Antibe Therapeutics Announces Strategic Licensing Deal for Lead Drug in South Korea
Antibe Therapeutics announced that it has entered into an exclusive licensing agreement with Kwang Dong Pharmaceutical for the development and commercialization of Antibe’s lead drug, ATB-346, in South Korea.